ELAPOR1

Across TCGA pan-cancer cohorts, ELAPOR1 Mutation is linked to patient survival in 7 of 34 cancer types, making it a survival-associated ELAPOR1 data layer compared with 28 for mass-spec protein and 3 for mass-spec protein.

The strongest signal is observed in lymphoid neoplasm diffuse large b-cell lymphoma (DLBC), where higher ELAPOR1 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated ELAPOR1 expression acts as an unfavorable survival marker, although some lineages such as STAD show a favorable association.

DLBC, STAD, and LUSC are the cancer types where ELAPOR1 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
DLBC	OS	Median	II,III,IV	0.172	0.949	<.001	30	view →
STAD	OS	Median	III,IV	1.000	0.352	.017	11	view →
LUSC	OS	Median	II,III,IV	0.181	0.732	.009	6	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
LIHC	DFS	Median	II,III,IV	0.053	0.427	.003	6	view →
KICH	DFS	Median	All	0.121	0.867	.023	5	view →
LGG	DFS	Median	All	0.216	0.728	.022	3	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

ELAPOR1–DLBC (OS)

Open the DLBC breakdown →